Xanadu and University of Alberta Partner to Accelerate Photodynamic Cancer Drug Discovery

Photonic quantum computing developer Xanadu Quantum Technologies Limited (NASDAQ/TSX: XNDU) has announced a strategic research partnership with the University of Alberta to engineer novel quantum algorithms for oncology and pharmaceutical drug design. Led by Xanadu's algorithms team and Professor Alex Brown, Chair of the Department of Chemistry at the University of Alberta, the project focuses on modeling complex light-matter interactions in photosensitizers—light-activated chemical compounds utilized in targeted photodynamic cancer therapy (PDT).

Photodynamic therapy uses light-activated compounds to selectively destroy localized tumor cells while minimizing systemic damage associated with traditional chemotherapy. However, designing photosensitizer molecules classically presents a severe computational bottleneck: predicting excited-state dynamics, wavelength sensitivity, and singlet oxygen generation efficiency requires modeling non-adiabatic light-matter coupling that traditional density functional theory (DFT) and classical quantum chemistry approximations struggle to resolve.

[ Xanadu & UAlberta Photodynamic Quantum Workflow ] │ ┌────────────────────────────────────┼────────────────────────────────────┐ ▼ ▼ ▼ Photosensitizer Target Systems Photonic Quantum Simulation Stack Early Fault-Tolerant Application • Excited-State Photodynamics. • PennyLane Quantum Software Stack. • Quantum Photodynamic Algorithms. • Wavelength Sensitivity Mapping. • Light-Matter Coupling Solvers. • Accelerates PDT Oncology Pipeline. • Singlet Oxygen Efficiency. • Photonic Fault-Tolerant Roadmaps. • Bypasses Classical Simulation Limits.

The collaboration pairs Xanadu’s fault-tolerant algorithm pipeline and PennyLane open-source software stack with Professor Brown’s benchmarking expertise in computational photodynamics:

• Light-Matter Simulation: Developing fault-tolerant quantum algorithms capable of simulating excited-state dynamics in complex photosensitizers beyond classical computational limits.

• Property Optimization: Mapping specific absorption spectra and energy-transfer pathways to engineer photosensitizers with higher selectivity and therapeutic efficacy.

• PennyLane Integration: Expanding PennyLane’s quantum chemistry modules to incorporate specialized algorithms for photo-activated molecular systems.

Led by Xanadu Founder and CEO Dr. Christian Weedbrook and Professor Alex Brown, the partnership expands Xanadu's life sciences computational chemistry stack as it advances its fault-tolerant room-temperature photonic hardware architecture.

Review the official partnership release on GlobeNewswire here.

August 13, 2026